☰

Michael O. Clarke, Ph.D. - Publications

Affiliations: 
2005 Stanford University, Palo Alto, CA 
Area:
Organic, Organometallic, Bioorganic, and Medicinal Chemistry
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, ... ... Clarke MO, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. PMID 26934220 DOI: 10.1038/nature17180  0.8
2015 Clarke MO, Mackman R, Byun D, Hui H, Barauskas O, Birkus G, Chun BK, Doerffler E, Feng J, Karki K, Lee G, Perron M, Siegel D, Swaminathan S, Lee W. Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. Bioorganic & Medicinal Chemistry Letters. 25: 2484-7. PMID 25978965 DOI: 10.1016/j.bmcl.2015.04.073  0.8
2014 Bush CO, Pokrovskii MV, Saito R, Morganelli P, Canales E, Clarke MO, Lazerwith SE, Golde J, Reid BG, Babaoglu K, Pagratis N, Zhong W, Delaney WE, Paulson MS, Beran RKF. A small-Molecule inhibitor of hepatitis C virus infectivity Antimicrobial Agents and Chemotherapy. 58: 386-396. PMID 24165192 DOI: 10.1128/AAC.02083-13  0.8
2014 Lazerwith SE, Lew W, Zhang J, Morganelli P, Liu Q, Canales E, Clarke MO, Doerffler E, Byun D, Mertzman M, Ye H, Chong L, Xu L, Appleby T, Chen X, et al. Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection. Journal of Medicinal Chemistry. 57: 1893-901. PMID 24144213 DOI: 10.1021/jm401420j  0.8
2013 Fenaux M, Eng S, Leavitt SA, Lee YJ, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, et al. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrobial Agents and Chemotherapy. 57: 804-10. PMID 23183437 DOI: 10.1128/AAC.02052-12  0.8
2012 Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney IV WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, et al. Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease Bioorganic and Medicinal Chemistry Letters. 22: 2629-2634. PMID 22366653 DOI: 10.1016/j.bmcl.2012.01.017  0.8
2012 Sheng XC, Casarez A, Cai R, Clarke MO, Chen X, Cho A, Delaney WE, Doerffler E, Ji M, Mertzman M, Pakdaman R, Pyun HJ, Rowe T, Wu Q, Xu J, et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorganic & Medicinal Chemistry Letters. 22: 1394-6. PMID 22244938 DOI: 10.1016/j.bmcl.2011.12.038  0.8
2012 Clarke MO, Byun D, Chen X, Doerffler E, Leavitt SA, Sheng XC, Yang CY, Kim CU. Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease. Bioorganic & Medicinal Chemistry Letters. 22: 1095-8. PMID 22189140 DOI: 10.1016/j.bmcl.2011.11.107  0.8
2012 Pyun HJ, Clarke MO, Cho A, Casarez A, Ji M, Fardis M, Pastor R, Sheng XC, Kim CU. Synthesis of 1-amino-2-vinylcyclopropane-1-phosphinates. Conversion of a phosphonate to phosphinates Tetrahedron Letters. 53: 2360-2363. DOI: 10.1016/j.tetlet.2012.02.111  0.8
2011 Lazerwith SE, Bahador G, Canales E, Cheng G, Chong L, Clarke MO, Doerffler E, Eisenberg EJ, Hayes J, Lu B, Liu Q, Matles M, Mertzman M, Mitchell ML, Morganelli P, et al. Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors. Acs Medicinal Chemistry Letters. 2: 715-9. PMID 24900257 DOI: 10.1021/ml200163b  0.8
2011 Clarke MO, Chen X, Cho A, Delaney WE, Doerffler E, Fardis M, Ji M, Mertzman M, Pakdaman R, Pyun HJ, Rowe T, Yang CY, Sheng XC, Kim CU. Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease. Bioorganic & Medicinal Chemistry Letters. 21: 3568-72. PMID 21601450 DOI: 10.1016/j.bmcl.2011.04.125  0.8
2005 Wender PA, Clarke MO, Horan JC. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs. Organic Letters. 7: 1995-8. PMID 15876038 DOI: 10.1021/ol0504650  0.8
2004 Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Current Drug Discovery Technologies. 1: 1-11. PMID 16472215  0.8
2003 Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, therapeutic leads, and drug delivery systems Pure and Applied Chemistry. 75: 143-155.  0.8
2002 Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM. The practical synthesis of a novel and highly potent analogue of bryostatin. Journal of the American Chemical Society. 124: 13648-9. PMID 12431074 DOI: 10.1021/ja027509+  0.8
Show low-probability matches.